Roger  Bird net worth and biography

Roger Bird Biography and Net Worth

Roger M. Bird serves as Senior Vice President - U.S. Nutrition of the Company. Between 2009 to 2015 he is Divisional Vice President and General Manager, China and Hong Kong, Nutritional Products. He is Elected Corporate Officer 2017.

What is Roger Bird's net worth?

The estimated net worth of Roger Bird is at least $6.58 million as of September 1st, 2020. Mr. Bird owns 56,630 shares of Abbott Laboratories stock worth more than $6,579,273 as of November 20th. This net worth evaluation does not reflect any other investments that Mr. Bird may own. Learn More about Roger Bird's net worth.

How do I contact Roger Bird?

The corporate mailing address for Mr. Bird and other Abbott Laboratories executives is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. Abbott Laboratories can also be reached via phone at (224) 667-6100. Learn More on Roger Bird's contact information.

Has Roger Bird been buying or selling shares of Abbott Laboratories?

Roger Bird has not been actively trading shares of Abbott Laboratories during the last ninety days. Most recently, Roger Bird sold 6,290 shares of the business's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $108.73, for a transaction totalling $683,911.70. Following the completion of the sale, the senior vice president now directly owns 56,630 shares of the company's stock, valued at $6,157,379.90. Learn More on Roger Bird's trading history.

Who are Abbott Laboratories' active insiders?

Abbott Laboratories' insider roster includes Hubert Allen (Executive Vice President, General Counsel and Secretary), Roxanne Austin (Director), Roger Bird (SVP), Brian Blaser (Insider), Philip Boudreau (VP), Sharon Bracken (Insider), John Capek (EVP), Jaime Contreras (SVP), Michael Dale (SVP), Lisa Earnhardt (EVP), Robert Ford (Chairman), Robert Ford (CEO), Robert Funck (CFO), Robert Funck, Jr. (EVP), Robert Funck, Jr. (EVP), Stephen Fussell (EVP), John Ginascol (EVP), Sammy Karam (SVP), Michelle Kumbier (Director), Andrew Lane (EVP), Joseph Manning (SVP), John Mccoy Jr. (VP), Nancy Mckinstry (Director), Mary Moreland (EVP), Louis Morrone (SVP), Phebe Novakovic (Director), Michael Pederson (SVP), Daniel Salvadori (EVP), Christopher Scoggins (SVP), Daniel Starks (Director), Julie Tyler (SVP), Andrea Wainer (EVP), Jared Watkin (SVP), Miles White (Chairman), Randel Woodgrift (SVP), and Brian Yoor (CFO). Learn More on Abbott Laboratories' active insiders.

Are insiders buying or selling shares of Abbott Laboratories?

During the last year, insiders at the healthcare product maker sold shares 9 times. They sold a total of 246,090 shares worth more than $28,051,118.59. The most recent insider tranaction occured on September, 12th when CEO Robert B Ford sold 141,679 shares worth more than $16,492,852.39. Insiders at Abbott Laboratories own 0.5% of the company. Learn More about insider trades at Abbott Laboratories.

Information on this page was last updated on 9/12/2024.

Roger Bird Insider Trading History at Abbott Laboratories

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/1/2020Sell6,290$108.73$683,911.7056,630View SEC Filing Icon  
3/13/2019Sell9,188$79.06$726,403.2860,195View SEC Filing Icon  
3/9/2018Sell8,262$62.75$518,440.5058,574View SEC Filing Icon  
4/27/2017Sell5,600$43.82$245,392.0051,313View SEC Filing Icon  
2/22/2017Sell13,222$45.02$595,254.4463,910View SEC Filing Icon  
4/27/2015Sell28,548$47.57$1,358,028.36View SEC Filing Icon  
See Full Table

Roger Bird Buying and Selling Activity at Abbott Laboratories

This chart shows Roger Bird's buying and selling at Abbott Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Abbott Laboratories Company Overview

Abbott Laboratories logo
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Read More

Today's Range

Now: $116.18
Low: $115.54
High: $116.77

50 Day Range

MA: $115.55
Low: $112.23
High: $119.39

2 Week Range

Now: $116.18
Low: $99.71
High: $121.64

Volume

1,760,152 shs

Average Volume

5,680,344 shs

Market Capitalization

$201.51 billion

P/E Ratio

35.31

Dividend Yield

1.90%

Beta

0.72